The anti-inflammatory effect of polymeric deflazacort nanocapsules (NC-DFZ) was investigated, and possible improvement of epithelial barrier function using filter grown monolayers of Calu-3 cells was assessed. NC prepared from poly(e-caprolactone) (PCL) had a mean size around 200 nm, slightly negative zeta potential ($À8 mV), and low polydispersity index (<0.10). Encapsulation of DFZ had an efficiency of 85%. No cytotoxic effects were observed at particle concentration of 9.85 Â 10 11 NC/ml, which was therefore chosen to evaluate the effect of NC-DFZ at 1% (w/v) of PCL and 0.5% (w/v) of DFZ on the epithelial barrier function of Calu-3 monolayers. Nanoencapsulated drug at 0.5% (w/v) increased transepithelial electrical resistance and decreased permeability of the paracellular marker sodium fluorescein, while non-encapsulated DFZ failed to improve these parameters. Moreover, NC-DFZ reduced the lipopolysaccharide (LPS) mediated secretion of the inflammatory marker IL-8. In vitro dissolution testing revealed controlled release of DFZ from nanocapsules, which may explain the improved effect of DFZ on the cells. These data suggest that nanoencapsulation of pulmonary delivered corticosteroids could be advantageous for the treatment of inflammatory conditions, such as asthma and chronic obstructive pulmonary diseases.
Introduction
As advanced drug carriers systems, nanocapsules (NC) have relevant technological advantages in the pharmaceutical field, such as the ability not only to avoid the burst release of drugs, but also to improve the effects of bioactive compounds [1, 2] . The promising results reported for poly(e-caprolactone)-based nanoparticles make such NC interesting from the pharmaceutical technology standpoint, due to the broad applications in various therapeutic targets, like cutaneous [3] and parenteral delivery [4] .
Lungs represent an attractive route for the administration of inhalation nanopharmaceuticals, as this class of drugs affords to control release and thus premature pulmonary clearance of locally topically acting drugs. [5] [6] [7] . This is particularly true for antiinflammatory drugs used to control diseases such as asthma and chronic obstructive pulmonary disease (COPD). In most cases glucocorticoids are the first choice therapy due to their antiinflammatory activity, which is based mainly on the downregulation of proinflammatory cytokines [8, 9] .
Human cell culture models have attracted increasing interest as a preclinical tool to assess toxicity and efficacy of active pharmacological ingredients and their formulations [10] , also affording to reduce the use of animals [11] . Previous studies have demonstrated that the physicochemical characteristics of NC such as surface charge [12] , stabilizers and polymers [13, 14] may trigger cytotoxic effects, which could limit their applications. Therefore, studies of the interaction between nanoparticles and biological systems are needed in order to improve current understanding of the phenomenon and to design innovative nanocarriers for therapeutic applications.
This study evaluated the safety and efficacy of poly(e-caprolac tone)-based NC as potential nanocarrier for pulmonary delivery. For this purpose, cytotoxicity studies of these NC were carried out in representative human alveolar (A549) and bronchial http://dx.doi.org/10.1016/j.ejpb.2017.05.006 0939-6411/Ó 2017 Elsevier B.V. All rights reserved.
(Calu-3) epithelial cell models. The maximally tolerated dose using the number of particles was determined as a parameter of cytotoxicity. Furthermore, the effect of the nanoencapsulation of the glucocorticoid deflazacort (DFZ) on the epithelial barrier function as measured by transepithelial electrical resistance (TEER) has been assessed. Similarly, the ability to reduce the expression of IL-8 in Calu-3 was also evaluated. Glucocorticoids are widely used to treat lung diseases [8] . The hypothesis tested in the present study was the improvement of their anti-inflammatory and enhancer effect on the airway barrier integrity by their nanoencapsulation and subsequent controlled release. Therefore, DFZ was chosen due to its higher anti-inflammatory activity and lesser side effects, compared with other corticosteroids [15] . Moreover, solubility characteristics of DFZ was also taken into account to assure a good encapsulation efficiency [16] .
Material and methods

Materials
Poly(e-caprolactone) (PCL) (MW: 80.000) was purchased from Sigma-Aldrich (São Paulo, Brazil) and medium-chain triglycerides (MCT) were bought from Delaware (São Paulo, Brazil). Polysorbate 80 was supplied by Henrifarma (São Paulo, Brazil) and deflazacort was purchased from Pharma Nostra (São Paulo, Brazil). Lipopolysaccharide (LPS) from Escherichia coli O111.B4 was purchased from Sigma Ò (St. Louis, USA). Sigma Dialysis bags (Spectra Por 7, 10 kD, Spectrum Laboratories, USA) were purchased from Bioagency (São Paulo, Brazil). HPLC grade acetonitrile was acquired from Tedia (São Paulo, Brazil). An analytical balance was used to weigh all the solid chemicals (Model AUX 220, Shimazdu Corporation, Kyoto, Japan). All other chemicals and solvents used in this study were of pharmaceutical grade and were used as received.
Preparation of polymeric nanocapsules
NC liquid suspensions were prepared by interfacial deposition of preformed polymer [17, 18] . The organic phase consisted of an acetone solution (67 ml) containing poly(e-caprolactone) (0.25 g) and MCT (0.75 ml) as oily core. The formulations containing glucocorticoid were prepared at a concentration of 0.5 mg/ml (NC-DFZ). The aqueous phase (134 ml) contained 0.193 g of polysorbate 80 (surfactant). All suspensions were prepared in triplicate, stored at room temperature (25 ± 2°C) and protected from light in amber glass flasks until analysis. Particle size and polydispersity index (PDI) were determined by photon correlation spectroscopy (three measurements/batch; two runs of 30 s/measurement, 25°C) after adequate dilution of an aliquot of the suspensions in purified water (Zetasizer Nanoseries, Malvern Instruments, Worcestershire, UK). Measurement range of the equipment was between 0.6 nm and 6 lm. Zeta potentials were determined using the same instrument at 25°C, after the dilution of the samples in 10 mM NaCl in aqueous solution (three measurements/batch; 10 runs/measurement, 25°C).
Determination of loading rate and encapsulation efficiency
Loading rate and encapsulation efficiency were determined by liquid chromatography (LC-10AVP Pump, UV-vis SDP-10AVP, Shimadzu, Japan) using a previously validated methodology [16] . The method was linear (r 2 = 0.9999) in the range of 5-40 lg/ml, accurate (recovery: 95.75 ± 0.5%), and precise (R.S.D.: <1.41% for repeatability and <2.37% for intermediate precision). Specificity was tested in the presence of the suspension adjuvants, which did not show any influence on the DFZ assay. The encapsulation efficiency (%) was determined by the ultrafiltration/centrifugation technique (Ultrafree-MC10.000 MW, Millipore, UDA), at 1000 rcf for 10 min. All analysis were performed in triplicate.
Particle concentration and surface area
The nanocapsule number density (NC/ml) of suspension was determined using two independent methods: turbidimetry and nanoparticle tracking analysis (NTA).
Turbidimetry
Turbidity s (cm À1 ) was determined according to a previously described method [19, 20] . Firstly, the lower wavelength in the UV-visible region, where there is no photon absorption, was determined in order to guarantee that scattering was the only phenomenon of the interaction between light and matter due to the presence of the particles in suspension. The wavelength of 382 nm was chosen based on a sample of NC suspension analyzed using a Shimadzu Ò UV-160PC spectrophotometer. Then, three batches of nanocapsules suspension were prepared and diluted (MilliQ Ò water) in such a range so as to obey the Lambert-Beer law. Turbidy (s) was calculated from the absorbance signal A of the equipment, as given in Eq. (2):
where b (cm) is the optical cell path length, s is a function of the particle diameter d (cm), N is the particle concentration N (particles cm
À3
), Q is a dimensionless quantity, which is the extinction efficiency as following Eq. (3):
At a fixed relative refractive index, it is possible to calculate Q as given in Eq. (4):
where d (cm) is the particle diameter, a (g cm À3 ) is the particle density, and K (cm 2 g À1 ) is the sample extinction coefficient, calculated using the Eq. (5):
where c (g cm
) is the sample concentration.
Nanoparticle tracking analysis (NTA)
NTA analysis was performed using a NanoSight Ò LM10 (NanoSight, Amesbury, UK), equipped with a sample chamber with a 640-nm laser. NC suspensions were diluted (20.000Â) in MilliQ Ò water and injected in the pre-calibrated chamber with a syringe. The light scattered was tracked by a digital camera for 60 s [21, 22] .
Surface area (S)
The surface area (cm 2 /ml) of the nanocapsules was calculated from the result of the number of particles according to a previous study [23] using Eq. (6):
where d (cm) is the particle diameter and N represents the number of nanocapsules per ml of suspension.
Cell cultures
The A549 cells (CCL-185; ATCC, Manassas, VA, USA) and Calu-3 (HTB-55; ATCC, Manassas, VA, USA) cell lines were grown using 75 cm 2 (T-75) flasks in humidified 5% CO 2 /95% atmospheric air incubator at 37°C. For A549 cells, RPMI-1640 with L-glutamine (PAA Laboratories GmbH, Pasching, Austria) supplemented with 10% fetal calf serum (FCS) (Lonza, Biosciences) was used as cell culture medium (CCM). For Calu-3 cells, the cell culture medium used was Minimum Essential Medium (MEM) with Earl's Salts and L-glutamine (PAA Laboratories GmbH, Pasching, Austria) and supplemented with 10% FCS, 1% non-essential amino acid (NEAA) solution and 1 mM sodium pyruvate (all from Sigma-Aldrich GmbH, Germany).
Cytotoxicity assays
Confluent A549 or Calu-3 cells were washed with buffered phosphate saline (PBS) and detached using trypsin-EDTA solution. Then, cells were pelleted by centrifugation. The pellet was suspended in cell culture media and the number of cells was counted using an automated cell counter (CASY, Roche Innovatis AG, Germany). A549 (10,000 cell/well) or Calu-3 (50,000 cell/well) cells were seeded separately into 96-well plates and incubated until cells reached confluence. Afterwards, cells were incubated with culture medium containing NC suspension of three different particle concentrations (9.85 Â 10 10 , 9.85 Â 10 11 , and 4.92 Â 10 12 NC/ ml of cell culture media) for 2, 24, and 48 h. The respective surface areas calculated from these particle concentrations were 1.24 Â 10 2 , 1.24 Â 10 3 , and 6.18 Â 10 3 cm 2 /ml.
In order to evaluate whether the surfactant of the NC (polysorbate 80) has any influence on NC cytotoxicity, an aqueous phase was prepared containing polysorbate 80 at the same concentration as used in the suspensions. Then, aliquots containing 0.03, 0.33, and, 1.60 mg/ml of polysorbate 80, whose volumes corresponded to 9.85 Â 10 10 , 9.85 Â 10 11 , and 4.92 Â 10 12 NC/ml respectively, were also prepared and evaluated in the cytotoxicity assays in the same cell culture medium used for the NC suspension. The supernatant from cell cultures was collected to assess lactate dehydrogenase (LDH) release, while the adherent cells were lysed to assess metabolic activity with Alamar blue (AB), as described below. All experiments were performed in triplicate.
Lactate dehydrogenase assay (LDH)
At each predetermined time, supernatants (100 ll) were transferred to 96-well plates and an equal volume of the LDH reagent mixture was added to each well. Absorbance was measured at 492 nm, cytotoxicity (%) was calculated using Triton X-100 as positive control (100% cytotoxicity), while cells with cell culture medium were used as negative control (0% cytotoxicity), according to Eq. (7): 
. Alamar Blue (AB) assay
The cells were washed with PBS and a solution containing 5% (v/ v) of AB reagent prepared in fresh cell culture medium was added to each well. After 3 h of incubation, AB fluorescence was measured at 540 and 595 nm of excitation and emission wavelengths, respectively [24, 25] . The positive and negative controls used in this experiment were prepared as described for the LDH assay. The results of both LDH and AB were quantified using a plate reader (Infinite M200 PRO, Tecan, Austria). and cultivated under liquid covered condition (LCC), in which cell culture medium was added in both apical (0.5 ml) and basolateral compartments (1.5 ml). TEER values were determined before and after NC incubation using a voltmeter (STX-2 EVOM Ò , World Precision Instruments, UK) [13] . Nanocapsules suspension (9.85 Â 10 11 NC/ml) without (NC) or with DFZ (NC-DFZ) as well as free drug (Free-DFZ) were incubated on confluent cells for 2, 24, and 48 h at 37°C. TEER values were calculated by subtracting the resistance of the membrane without cells (120 O) and the result corrected based on the area of inserts (1.12 cm 2 ).
Cell permeability to sodium fluorescein (FluNa)
Calu-3 cell monolayers were used for the permeability studies after 7-8 days of seeding, following a previous protocol [26] . After 24 h of the incubation of NC (9.85 Â 10 11 NC/ml) or NC-DFZ (at 0.5%), cell culture media of both apical and basolateral compartments were aspired and incubated with Krebs-Ringer buffer (KRB) at 37°C until equilibrium was reached. Sodium fluorescein permeability was evaluated by replacing KRB in the basolateral compartment and adding 20 ll of fluorescein solution (10 lg/ml)
to KRB in the apical chamber (donor). Aliquots of 200-ll were retrieved from the basolateral chamber (acceptor) after 0.5, 1, 1.5, 2, 2.0, and 3 h. During the test, the samples were transferred to 96-well plates, and fluorescence was measured using a fluorimeter (Infinite M200 PRO, Tecan, Austria). The excitation and emission wavelengths were 488 and 530 nm, respectively. Apparent permeability coefficients (P app ) were calculated using Eq. (8):
where dq/dt represents the linear transport rate of sodium fluorescein, A is the surface area of the insert, and C 0 is the initial concentration of sodium fluorescein in the apical chamber. For comparison, the permeability of sodium fluorescein after the treatment with the non-encapsulated form of DFZ (Free-DFZ) was also performed.
Interleukin-8 (IL-8) measurement
Confluent Calu-3 cells were stimulated with LPS (+LPS) at 100 ng/ml 24 h before exposure to NC, NC-DFZ (at 0.5%), or Free-DFZ (0.5%). The particle concentration used for NC and NC-DFZ was 9.85 Â 10 11 NC/ml. Non-encapsulated form of DFZ at 0.5% (Free-DFZ) was used. Wells containing stimulated Calu-3 cells with LPS but not treated were used as a control. For comparison, experiments without LPS (-LPS) were carried out as well, using wells containing non-stimulated Calu-3 cells with LPS and no treatment as a second control. After 24 and 48 h of exposure, aliquots of supernatants were collected and stored at -80°C upon analysis. IL-8 release was detected by flow cytometry using a FACScalibur flow cytometer (BD Biosciences Ò ) and a cytometric beads array kit (CBA). The results were analyzed using the FACP Array TM software.
In vitro drug release profile
In vitro DFZ release profile of NC-DFZ was evaluated (n = 3) using the dialysis bag method [17, 18] and polysorbate 80 at 2 % (w/v) in water as medium at 37°C to maintain sink conditions. The dialysis bag containing 1 ml of the sample (0.5 mg/ml). was placed in a 250-ml flask containing 200 ml of release medium under constant moderate stirring. The amount of 1 ml of the external medium was withdrawn from the system at a predetermined time interval, replaced by an equal volume of fresh medium, and filtered through a 0.45-lm membrane. DFZ was assayed in the samples by liquid chromatography (LC) according to the methodology previously described, as mentioned in Section 2.3.2 [16] . The diffusion of non-encapsulated form of DFZ across the dialysis bag was performed and used as control. For this purpose, an ethanolic solution of DFZ (DFZ-ES) at the same drug concentration of NC-DFZ was prepared.
Statistical analysis
Statistical analysis was carried out by analysis of variance (ANOVA). Post-hoc multiple comparisons were carried out applying Tukey's test at p-value 0.05 (SigmaStat Ò Statistical Program, Version 3.5, Jandel Scientific, USA).
Results
NC suspensions had a unimodal particle size distribution in the nanoscale range, as analyzed by laser diffractometry (Fig. 1) .
In addition, the particle size distribution profile obtained by laser diffraction showed a narrow range, with Span values lower than 1.7 ( Table 1) .
The measurements performed by photon correlation spectroscopy revealed that NC had mean particle size around 200 nm, polydispersity indexes below 0.1, pH value around 6.0, and zeta potential close to neutral (Table 2) . Moreover, the NC formulation containing the DFZ (NC-DFZ) had loading rate of 4.9 ± 0.03% and encapsulation efficiency of 85 ± 0.06%.
The particle concentration of NC suspension obtained using the spectroscopic method was 1.73 ± 0.46 Â 10 13 nanocapsules per ml of suspension. On the other hand, particle concentration obtained using the NTA method was N = 2.29 ± 0.45 Â 10 13 nanocapsules per ml of suspension. Fig. 2 shows the results obtained using the LDH assay after the incubation of NC in three different particle concentrations (9.85 Â 10 10 , 9.85 Â 10 11 or 4.92 Â 10 12 NC/ml) for 2, 24, and 48 h in A549 or Calu-3 cells. The particle concentration 4.92 Â 10 12 NC/ml was cytotoxic to A549 ( Fig. 2A) and Calu-3 cells (Fig. 2B ). On the other hand, no cytotoxic effect was observed for 9.85 Â 10 10 and 9.85 Â 10 11 NC/ml particle concentrations in both A549 and Calu-3 cells. Fig. 3 shows the cell viability using the AB assay in A549 (Fig. 3A) and Calu-3 ( Fig. 3B) 9.85 Â 10 11 NC/ml. Fig. 4 shows the results obtained in the LDH method for both A549 (Fig. 4A ) and Calu-3 ( Fig. 4B ) cells exposed only to polysorbate 80 (surfactant), which was used to prepare the NC suspensions.
In this test, three different concentrations of surfactant (0.03, 0.33, and 1.60 mg/ml), which correspond to its amount in Fig. 1 . Sizes distribution profiles obtained by laser diffraction considering the volume for polymeric nanocapsules (NC), polymeric nanocapsules and MEM (NC-MEM), polymeric nanocapsules and RPMI (NC-RPMI), and polymeric nanocapsules containing deflazacort (NC-DFZ) (n = 3). Thereby, polysorbate 80 did not show any cytotoxic effects in A549 neither Calu-3 cells at any of the concentrations tested. In the same way, Fig. 5 shows the cell viability using the AB assay for the same concentrations of surfactant described above. Both A549 (Fig. 5A ) and Calu-3 cells (Fig. 5B ) remained metabolically active, with survival rate ranging from 80 to 100% for 48 h. Fig. 6 shows the TEER measurements of the Calu-3 cells 24 h before and 2, 24, and 48 h after exposure to the treatments with NC and NC-DFZ (at 9.85 Â 10 11 particles NC/ml) and nonencapsulated DFZ (Free-DFZ). After 24 h, the TEER of NC-DFZ treated cell cultures was significantly increased (p < 0.05) compared to all other treatments (NC, Free-DFZ and cell culture medium). After 48 h such difference was no longer observed. Fig . 8A and B shows the levels of IL-8 cytokine in Calu-3 cells stimulated or not with LPS, respectively, after 24 and 48 h. Interleukin was quantified after the incubation of NC, NC-DFZ, and non-encapsulated DFZ (Free-DFZ). Regarding the non-stimulated LPS cells (Fig. 8A) , no significant differences of the levels of IL-8 were observed among all treatments after 24 h. However, treatments with NC-DFZ and Free-DFZ led to the release of lower IL-8 levels after 48 h in comparison with the control and the NC (p 0.05). However, Calu-3 cells stimulated with LPS (Fig. 8B) showed lower IL-8 levels after the treatment with Free-DFZ (24 h and 48 h) and NC-DFZ (48 h) in comparison with the controls (p 0.05).
The results obtained from in vitro drug diffusion profiles of nonencapsulated DFZ in an ethanolic solution (DFZ-ES) and release from NC (NC-DFZ) are depicted in Fig. 9 . It could be shown, that DFZ showed a faster diffusion through the dialysis bag from DFZ- Fig. 2 . Cell viability of the (A) A549 and (B) Calu-3 cell lines exposed to polymeric nanocapsules at different particle concentrations after 2, 24, and 48 h (n = 3) obtained using the lactate dehydrogenase (LDH) method. Fig. 3 . Cell viability of the (A) A549 and (B) Calu-3 cell lines exposed to polymeric nanocapsules at different particle concentrations after 2, 24, and 48 h (n = 3) obtained using the Alamar Blue (AB) assay.
ES. The amount of drug diffused after 8 h was around 90%, whereas DFZ release from NC reached only 35% in the same period. The amount of DFZ released from nanocapsules was about 50% and 83% after 24 and 48 h, respectively.
Discussion
Regarding the physicochemical characterization of NC, all suspensions showed the same size range (around 200 nm), independently of the presence of the drug. These results are consistent with other data reported in the literature for NC prepared by interfacial deposition of pre-formed polymer using PCL and non-ionic surfactants [27, 28] . NC suspension had a slight negative zeta potential, explained by the non-ionic coating layer (polysorbate 80) at the particle/water interface, which sterically stabilizes these nanoparticles [29] . Since any particle acquires charge in suspension, these NC could be considered neutral. This result is in agreement with similar NC suspensions prepared using PCL as polymer and polysorbate 80 as stabilizer. Also, the NC prepared with DFZ showed a loading rate of about 5 % (w/w), with 85 % (w/v) of drug loaded on the nanocapsules and 15% (w/v) as non-encapsulated drug (dispersed in water).
The total mass of a drug is classically used in pharmacology as a parameter of dose. In NC suspensions, where the solid and liquid states coexist, the high surface area of the particles induces interactions with biological systems and, for this reason, drugs or other active compounds may be delivered. Therefore, total mass is not predictive of surface area. However, the surface area may be evaluated calculating the number of particles in suspension. The estimation of the particle concentration is complex. This task involves a variety of methods to determine how many particles are available to reach defined targets [30] . Taking into account that a nanoscale range requires complementary techniques in order to improve the precision of the results, data obtained using either method led to a similar particle concentration, in the same magnitude. However, the spectroscopic method (turbidimetry) is less expensive and more complex to perform, compared to NTA. More- Fig. 4 . Cell viability of the (A) A549 and (B) Calu-3 cell lines exposed to polymeric nanocapsules at different particle concentrations after 2, 24, and 48 h (n = 3) obtained using the lactate dehydrogenase (LDH) assay. over, the particle concentration obtained by this method may vary by up to 10% [19] . Thus, the particle concentration obtained from NTA was chosen to calculate the doses in the subsequent in vitro studies. The different particle concentrations used in this study (9.85 Â 10 10 , 9.85 Â 10 11 , and 4.92 Â 10 12 NC/ml) correspond to 0.05, 0.57, and 2.84 mg/ml of particles, respectively. Before starting the cytotoxicity assays, aliquots of the NC suspension were mixed with both RPMI (NC-RPMI) or MEM (NC-MEM) cell culture media to a 1:1 ratio in order to assess the behavior of the particles in these media. The physicochemical parameters remained in the nanometric scale, with results practically unchanged in comparison with the original NC suspension. This result may be explained considering the absence of charge of the polymer and polysorbate 80, which could prevent nanocapsules aggregation or the formation of microstructures in the presence of both cell culture media.
Whereas one of the main functions of alveolar cells is gas exchange, bronchial epithelial cells play a key role in protection against external agents due to the secretion of mucus and the ciliary movement. Moreover, epithelial cells are able to secrete defense molecules i.e. interleukins. [31] . It is noteworthy to emphasize that NC studied in this work are not a model of active targeting. One of the purposes of the study was to evaluate the local effect of NC with or without DFZ. In order to find the particle concentration that does not harm the cells under in vitro conditions, cytotoxicity assays of the NC in representative cell lines of the alveolar (A549) or bronchial (Calu-3) lung regions were performed. Complementary tests, i.e. LDH and Alamar Blue, have been used as cell viability indicator in cytotoxic studies of nanoparticles [13, 32] . Only the particle concentration represented by the highest surface area was cytotoxic to A549 and Calu-3 cells. On the other hand, the results obtained for 9.85 Â 10 10 and 9.85 Â 10 11 NC/ml are supported by the AB test, where both A549 and Calu-3 cells remained metabolically active after 48 h of exposure to 9.85 Â 10 10 and 9.85 Â 10 11 NC/ml.
The results obtained from polysorbate 80 showed low cytotoxic effect in the LDH test in A549 and Calu-3 cells, regardless of its concentration. Therefore, the hypothesis of the influence of the surfactant on the cytotoxic effects shown by the higher particle concentration (4.92 Â 10 12 NC/ml) could be refuted. Taken together, these results show that the cytotoxic effects demonstrated only by the higher number of NC are not cell-specific. It may be suggested that this effect may be a consequence of the physical effect of the nanoparticles due to the overexposure of these cells to a high number of particles. Based on these data, the particle concentration of 9.85 Â 10 11 NC/ml was chosen for the next experiments, since this particle concentration was not harmful to A549 and Calu-3 cells in the evaluated conditions. To the best of our knowledge, no previous study has specifically addressed the influence of poly(e-caprolactone)-based polymeric nanocapsules on the epithelial barrier of Calu-3 monolayers. Therefore, the influence of the nanoencapsulation of DFZ on the epithelial barrier of Calu-3 cells was evaluated. For comparison, the same DFZ concentration used to prepare such NC was solubilized in a cell culture medium containing DMSO at 1% (v/v) and used as non-encapsulated form of the drug (Free-DFZ). Firstly, a NC suspension containing DFZ at 0.5% (NC-DFZ) was produced. The presence of the drug did not alter the physicochemical characteristics of the original NC or particle distribution.
Regarding all TEER values, the treatments did not damage the epithelial barrier during the experiment, regardless of the presence of drug. Interestingly, measured TEER values for NC-DFZ were higher than those observed in all other treatments after 24 h. This finding is remarkable, because the TEER measurement of the association between NC and DFZ seems to have an improved effect on this parameter, in comparison with TEER values for NC or Free-DFZ. It has been reported that glucocorticoids can increase TEER in Calu-3 [33] ; however, the effect of NC-DFZ treatment could be useful to improve the epithelial barrier. The injured epithelial barrier (i.e. in asthmatics and allergic rhinitis) has been reported to be an entry route for pathological agents, which in turn increase the susceptibility to allergens and viral infections [34, 35] . On the other hand, there was no significant difference of TEER values among the treatments after 48 h. Therefore, since TEER values reflect the integrity of the epithelial barrier, the association between NC and a glucocorticoid (DFZ) may be suggested as a potential approach to improve the epithelial integrity.
The permeability of compounds across the epithelial barrier depends on their integrity [31] . Therefore, a transport study to evaluate the influence of NC-DFZ on the paracellular permeability was carried out by measuring the permeability of sodium fluorescein (FluNa), a hydrophilic molecule typically used as paracellular marker. A tendency of NC-DFZ to decrease FluNa permeability was observed, corroborating the improvement of TEER values. Studies have reported that a decrease in TEER with the subsequent increase of paracellular permeability of fluorescent markers may promote the entry of viruses or allergens in the lung [36] [37] [38] . In these cases, NC-DFZ formulation could be proposed to minimize the lung vulnerability to pathogens due to its ability to decrease paracellular transport and to increase TEER, besides the known anti-inflammatory and immunosuppressive activities of this glucocorticoid. Moreover, the result obtained for NC-DFZ nanocapsules suspension are supported by their compatibility with epithelial cells, as previously discussed. NC-DFZ may deliver the drug without compromising the integrity of the transepithelial barrier, taking into account a local effect.
The anti-inflammatory potential of NC-DFZ was assessed by measuring IL-8 cytokine release in LPS pre-stimulated Calu-3 cells. The endotoxin LPS, derived from gram-negative bacteria, induces the release of IL-8 mainly by activation of the nuclear factor-jB (NF-jB). One of its functions is to control the transcription of inflammatory responses in immunocompetent cells [39] . Firstly, experiments without the stimulation of IL-8 by LPS (-LPS) in Calu-3 cells were carried out in order to evaluate whether NC may, by themselves, stimulate IL-8 secretion. The presence of such NC did not stimulate the release of this cytokine. In this case, the hypothesis whether this kind of nanoparticles could trigger the release of proinflammatory molecules was discarded. However, when the drug (DFZ) was present in the treatment (NC-DFZ or Free-DFZ) a decrease in the IL-8 release after 48 h was observed, which may be explained by the anti-inflammatory properties of DFZ.
Regarding the results obtained from the set of experiments where IL-8 secretion in Calu-3 cells was stimulated by LPS (+LPS), treatment with control (cell culture media), Free-DFZ or NC showed the same IL-8 levels, regardless of the time. This result supports the idea that NC by themselves did neither induce nor reduce the secretion of IL-8 in the absence or presence of LPS, respectively. The decrease in IL-8 levels after the treatment with Free-DFZ for 24 and 48 h in comparison with the control was expected, considering the known anti-inflammatory activity of such glucocorticoid. However, treatment with NC-DFZ showed a decrease in the IL-8 levels only after 48 h, which could be explained by a controlled drug release from nanocapsules. In order to test this hypothesis, drug release studies were carried out.
Drug release profiles showed the sustained release of the glucocorticoid from NC-DFZ, reaching release values close to 85% after 48 h. In contrast, the DFZ-ES (representing the Free-DFZ) showed a fast diffusion profile, with more than 50% of the drug available in the medium after 4 h. In this scenario, the greater decrease of IL-8 promoted by the exposure of Calu-3 cells to NC-DFZ for 48 h could be explained based on the controlled release profile provided by the formulation, confirming our hypothesis. The ability to avoid the fast drug diffusion is one of the main features of such NC [40, 41] , which in turn prolongs or delays the time drugs remain active, improving therapeutic management. Along with these properties, the association between NC and the glucocorticoid is an interesting approach to restore the epithelial barrier function, as discussed earlier, and to avoid the worsening of lung pathologies, with the subsequent release of the glucocorticoid to control the inflammation process. Moreover, the self-clearing mechanism naturally promoted by the lung (mucocilliary clearance) should be taken in account. The role of the particle size on their lung deposition and clearance has been reported and should be deeply evaluated in next studies specifically for PCL nanocapsules. Previous reports in the literature showed half-life time of nanoparticle lung clearance between 10 and 96 h, depending on the drug nanocarrier [42, 43] . This reasonable lung retention time is suitable to reduce the drug administration frequency as well as for controlled drug release systems [42] , like PCL nanocapsules. It is important to emphasize that the prolonged effect can be considered an important advantage, particularly for chronic pulmonary diseases, whose pharmacological management requires prolonged therapies. Under these circumstances, several doses of glucocorticoids are recommended to control the inflammation, and are often administered through the local route [8, 9] . Besides the influence of the controlled drug release on the improved effects of the nanoencapsulated DFZ, other mechanisms should be further evaluated in next studies, as the effect on the drug/nanoparticles uptake by the lung cells. Furthermore, the toxicity of the proposed formulation (DFZ-loaded nanocapsules) should be evaluated in the future by means of in vitro and in vivo studies as well as in vivo studies on PCL nanocapsules deposition, retention and clearance.
Conclusion
The nanoencapsulation of the DFZ was essential to improve the integrity of the epithelial barrier as well as to decrease the paracellular permeability in Calu-3 cells. Moreover, NC-DFZ decreases IL-8 secretion, keeping anti-inflammatory efficacy based on the advantage of controlled drug release. It is possible that this effect starts after the improvement of the epithelial barrier. Therefore, the association between these polymeric nanocapsules and a glucocorticoid is suggested as a potential and innovative therapeutic approach for pulmonary diseases, since it combines the ability to restore the epithelial barrier integrity and anti-inflammatory effects.
Declaration of interest
The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the article.
